

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : Divisional of 09/514,278
Applicant : Sheldon B. GREER
Filed : Herewith
TC/A.U. : 1614
Examiner : Rebecca Cook (Parent)

Docket No. : 2954-128
Customer No. : 06449
Confirmation No. :

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The material listed on the accompanying forms PTO-1449 and forms PTO-892, from the parent application having U.S. serial Number 09/514,278, is cited in compliance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Applicant respectfully requests that the Examiner consider these references with respect to the present application. Copies of these references can be found with the parent application and, accordingly, will not be resubmitted unless requested by the Examiner.

Respectfully submitted,

By



Robert B. Murray
Attorney for Applicants
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

| | | | |
|--------------------------------------------------------------------------------|------------------------------------------------------------|-------------------------|---------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. | SERIAL NO. |
| | | 2954-128 | New Appln. |
| | | APPLICANT GREER | |
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | | FILING DATE Herewith | GROUP 1614 |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|---------------|----------------|
| | AA | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO PART. | | |
|--|----|-----------------|----------|---------|-------|---------------|-----------------------------|--|--|
| | AC | WO 85/01871 | 05/09/85 | PCT | | | | | |
| | AD | WO 96/26743 | 09/06/96 | PCT | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | AE | Wollner et al. Abstract, "Toxicity of Hepatic Arterial 5 Bromo-2'-Deoxyuridine Followed by Yttrium-90 Microspheres in Dogs", Proc. Am. Soc. Clin. Oncol. Annu. Meet., May 4-6, 1986, Vol. 5, page 46 |
| | AF | Boothman et al. Abstract, "Potentiation of Halogenated Pyrimidine Radiosensitizers in Human Carcinom Cells by Beta.-1apachone(3,4-dihydro-2,2-dimethyl-2H-naphtho'1,2-b!pyra 5,6-dione), a Novel DNA Repair Inhibitor", Cancer Res. (1987), Vol. 47, pp. 5361-66. |
| | AG | Perez et al. Abstract, "Marked Radiosensitization of Cells in Culture to X-Ray by 5-chlorodeoxycytidine Coadministered with Tetrahydrouridine, and Inhibitors of Pyrimidine Biosynthesis", Int. J. Radiat. Oncol., Biol., Phys., (1984), Vol. 10, pp. 1453-58 |
| | AH | Zucchetti et al. Abstract, "Temozolomide-Induced Differentiation of K562 Leukemia Cells is not Mediated by Gene Hypomethylation", Biochem. Pharmacol. (1989), Vol. 38, pp. 2069-75 |
| | AI | Mundinger et al. Abstract, "Post-Operative Stereotactic Curie-Therapy Using the Iridium-192 GammaMed Contact Irradiation Apparatus Combined with Radio-Sensitizers in Treating Multiform Glioblastomas", ACTA Neurochirurgica, Vol. 42, pp. 73-77 (1978) |
| | AJ | Greer et al. Abstract, "5-Chlorodeoxycytidine, a Radiosensitizer Effective Against RIF-1 and Lewi Lung Carcinoma, is Also Effective Against a DMBA-Induced Mammary Adenocarcinoma and the EMT-6 Tumor in BALB/c Mice", Int. J. Radiat. Oncol., Biol., Phys. (1992), Vol. 22, pp. 505-10 |
| | AK | Kalinich et al. Abstract, "Radioprotective Properties of DNA Methylation-Disrupting Agents", International Journal of Radiation Biology, (1991), Vol. 59, pp. 1217-26 |
| | AL | Thibault et al. Abstract, "A Phase II Study of 5-aza-2'deoxyctidine (decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer", http://www.Oncolink.Com/Cancernet/98/Aug/708471.HTML&50 , Tumori, Vol. 84, pp. 87-89 (1998) |
| | AM | Lawrence et al. Abstract, "Selective Radiosensitization and Cytotoxicity of Human Melanoma Cells using Halogentated Deoxycytidines and Tetrahydrouridine Retrieved from STN", Int. J. Radiat. Oncol. Biol. Phys. (1989), pp. 1243-46 |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

Notice of References Cited

Application/Control No.

2954-128

Applicant(s)/Patent Under
Reexamination
GREER, SHELDON B.

Examiner

Jerome D Goldberg

Art Unit

1614

Page 3 of 5

U.S. PATENT DOCUMENTS

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Name | Classification |
|---|---|--------------------------------------------------|-----------------|------|----------------|
| | A | US- | | | |
| | B | US- | | | |
| | C | US- | | | |
| | D | US- | | | |
| | E | US- | | | |
| | F | US- | | | |
| | G | US- | | | |
| | H | US- | | | |
| | I | US- | | | |
| | J | US- | | | |
| | K | US- | | | |
| | L | US- | | | |
| | M | US- | | | |

FOREIGN PATENT DOCUMENTS

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Country | Name | Classification |
|---|---|--------------------------------------------------|-----------------|---------|------|----------------|
| | N | | | | | |
| | O | | | | | |
| | P | | | | | |
| | Q | | | | | |
| | R | | | | | |
| | S | | | | | |
| | T | | | | | |

NON-PATENT DOCUMENTS

| * | | Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) | | | |
|---|---|-------------------------------------------------------------------------------------------|--|--|--|
| | U | Greer et al., Int. J. Radiat. Oncol., Biol., Phys. (1992), 22(3), 505-10 ABSTRACT ONLY | | | |
| | V | | | | |
| | W | | | | |
| | X | | | | |

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

| | | | |
|--------------------------------------------------------------------------------|------------------------------------------------------------|------------------|------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. | SERIAL NO. |
| | | 2954-128 | New Appln. |
| | | APPLICANT | |
| | | GREER | |
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | | FILING DATE | GROUP |
| | | Herewith | |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|------------------|----|--------------|----------|------------------|-------|-----------|-------------|
| | AA | 4,894,364 | 1/16/90 | Greer | 514 | 49 | |
| | AB | 5,985,266 | 11/16/99 | Link, Jr., et al | 424 | 93.21 | 7/30/97 |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | AC | Santos, O, Perez, L, Briggie, T, Boothman, D, Greer, S. 1990. Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine. <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 19:357-365. |
| | AD | Greer, S, Santos, O, Gottlieb, C, Schwade, J., Marion, S. 1990. 5-Chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and Lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice. <i>Int. J. Rad. Oncol. Biol. Phys.</i> 22:505-510. |
| | AE | Greer, S, Schwade, J, Marion, S. 1995. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation. <i>Int. J. Rad. Oncol. Biol. Phys.</i> 32:1059-1069. |
| | AF | Kim, C-H., Marquez, V., Mao, D., Haines, D., McCormack, J. 1986. Synthesis of pyrimidin-2-one nucleoside as acid-stable inhibitors of cytidine deaminase. <i>J. Med. Chem</i> 29:1374-1380. |
| | AG | Marquez, V. 1994. Inhibition of cytidine deaminase: mechanism and effects of the metabolism of antitumor agents. In: <i>Developments in Cancer Chemotherapy</i> , Robert I. Glazer, ed, CRC Press, Boca Raton, FL, pp. 92-114. |
| | AH | Kelly, J., Driscoll, J., McCormack, J., Roth, J., Marquez, V. 1986. Furanose-pyranose: isomerization of reduced pyrimidine and cyclic urea ribosides. <i>J. Med. Chem.</i> 29: 2351-2358. |
| | AI | Wempen, I., Duschinsky, R., Kaplan, L., and Fox, J. 1961. Organic and biological chemistry. Thiation of Nucleosides. IV. The synthesis of 5-fluoro-2'-deoxycytidine and related compounds. <i>J. Amer. Chem. Soc.</i> 83:4755-4766. |
| | AJ | Russell, K., Rice, G., Brown, J. 1986. <i>In vivo</i> and <i>in vitro</i> radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine. <i>Cancer Res.</i> 46:2883-2887. |
| | AK | Kinsella, T., Kunugi, K., Vielhuber, K., McCulloch, W., Liu, S-H., and Cheng, Y-C. 1994. An <i>in vivo</i> comparison of oral 5-Iodo-2'-deoxyuridine and 5-iodo-2'-pyrimidinone-2'-doeoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. <i>Cancer Res.</i> 54:2695-2700. |

| | | |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | AL | Wataya, Y., Santi, D., Hansch, C. 1977. Inhibition of <i>Lactobacillus casei</i> thymidylate synthetase by 5-substituted 2'-deoxyuridylates. Preliminary quantitative structure-activity relationship. <i>J. Med. Chem.</i> 20: 1469-1473. In: Balzarini, J., DeClerq, E., Mertes, M., Shugar, D., Torrence, P. 1982. 5-Substituted 2'-deoxyuridines: Correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. <i>Biochem. Pharmacol.</i> 31:3673-3682. |
| | AM | Wataya, Y., Santi, D. 1975. Thymidylate synthetase catalyzed dehalogenation of 5-bromo- and 5-iodo-2'-deoxyuridylate. <i>Biochem. Biophys. Res. Commun.</i> 67: 818-823. |
| | AN | Caradonna, S, Cheng, Y-C. 1980. The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase α in the metabolism of FUDr in human tumor cells. <i>Mol. Pharmacol.</i> 18:513-520. |
| | AO | Hirota, Y, Yoshioka, A, Tanaka, S, et al. 1989. DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells. <i>Cancer Res.</i> 49:915-919. |
| | AP | Jones, P, Taylor, S. 1980. Cellular differentiation, cytidine analogs, and DNA methylation. <i>Cell.</i> 20:85-93. |
| | AQ | Kaysen, J, Spriggs, D, Kufe, D. 1986. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. <i>Cancer Res.</i> 46: 4534-4538. |
| | AT | Osterman, D., DePillis, G., Wu, J. Matsuda, A., Santi, D. 1988. 5-Fluorocytosine in DNA is a mechanism-based inhibitor of <i>HhaI</i> methylase. <i>Biochemistry.</i> 27:5204-5210. |
| | AU | Yang, A., Shen, J-C, Zingg, J-M, Jones P. 1995. <i>HhaI</i> and <i>HpaII</i> DNA methyltransferase bind DNA mismatches, methylate uracil and block DNA repair. <i>Nucl. Acids Res.</i> 23:1380-1387. |
| | AV | Jones, P, Rideout, W., III, Shen, J-C, et al. 1992. Methylation, mutation and cancer. <i>BioEssays.</i> 4:33-36. |
| | AW | El-Deiry, W., Nelkin, B., Celano, P., Yen, C., Falco, J., Hamilton, S., Baylin, S. 1991. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. <i>Proc. Natl. Acad. Sci. USA.</i> 88: 3470-3474. |
| | AX | Baylin, S. and Herman, J. 2000. Promoter hypermethylation and gene silencing in cancer. <i>Advances in Gene Tech: DNA, RNA and Cancer.</i> Miami Nature Biotechnology Winter Symposium, p. 43. |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |